Drug intelligence / Profile preview

amlodipine + atorvastatin

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

**Amlodipine + atorvastatin** is an oral fixed-dose combination of amlodipine, a dihydropyridine calcium-channel blocker, and atorvastatin, a competitive HMG-CoA reductase inhibitor. It is marketed as **Caduet** and is used when treatment with both agents is appropriate: amlodipine lowers blood pressure and treats angina through peripheral and coronary vasodilation, while atorvastatin lowers LDL cholesterol and other atherogenic lipoproteins. The combination is indicated for patients with hypertension or coronary artery disease/angina who also require lipid-lowering therapy and cardiovascular-risk reduction. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021540s049lbl.pdf))

Brand names
CaduetDuoda YiDuodayEnvacar
Other names
amlodipine and atorvastatinamlodipine besylate + atorvastatin calciumamlodipine besylate/atorvastatin calciumamlodipine/atorvastatin
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on amlodipine + atorvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + atorvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call